Stock Ratings / Health Care / NVCT / options

GERN (37) IRWD (69) ZVRA (40) CRMD (62) ⌘ Pro Terminal →

Nuvectis Pharma Inc. (NVCT) Options Positioning, Max Pain & Unusual Sweeps

$18.57 +1.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.57

Nuvectis Pharma Inc. (NVCT) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $605.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $18.57 (+0.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVCT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY NVCT SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (28% of score)

FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 41.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$21.12-11.9% Next Q

Q2 (-2Q)

Grade D$18.60+7.8% Next Q

Q3 (-1Q)

Grade D$20.05-7.4% Next Q

Current

Grade D-$18.57-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NVCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NVCT currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.45) and Max Pain ($19.50) forces dealer call-delta covering toward $30.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NVCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NVCT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NVCT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVCT)

✓Walkthrough of NVCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NVCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +116.94%🛡️ HOLDING TREND SUPPORT

2026-10-30O $18.46H $18.92L $18.20C $18.57VOL 168.9K

RES: $20.98SUP: $17.61SMA50: $21.45SMA200: $14.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NVCT Butterfly Map → + Track NVCT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NVCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NVCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NVCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVCT)

Health Care Rank #546 of 1016 ⚔️ GERN vs NVCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NVCT vs. GERN, IRWD, ZVRA, CRMD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nuvectis Pharma Inc. (NVCT) ranks #546 by composite RQD confidence (43/100, grade D-) and #419 by equity capitalization ($605.6M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with NVCT at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NVCT ACTIVE Nuvectis Pharma Inc.	D-	43/100	—	—	-35.0%	+1.14%	$605.6M	Benchmark Subject
GERN Geron Corporation	D-	37/100	—	—	-20.2%	-2.30%	$607.9M	/gern-vs-nvct →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C+	69/100	24.9x	—	85.0%	+0.28%	$598.2M	/irwd-vs-nvct →
ZVRA Zevra Therapeutics Inc.	D-	40/100	7.4x	—	-32.3%	+0.49%	$615.2M	/zvra-vs-nvct →
CRMD CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-6.83%	$595.5M	/crmd-vs-nvct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001875558

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuvectis Pharma Inc. (NVCT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.4M, operating cash flow of -$16.0M, and free cash flow of -$16.0M (-30.7% YoY). On the balance sheet, NVCT closed FY2025 with $31.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$26.4M	-$16.0M	-$16.0M	$31.7M	—
FY2024 (FY)	2024-12-31	$0	-$19.0M	-$12.2M	-$12.2M	$18.6M	—
FY2023 (FY)	2023-12-31	$0	-$22.3M	-$16.0M	-$16.0M	—	—

3. NVCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NVCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nuvectis Pharma Inc. (NASDAQ: NVCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $18.57 (+1.14% 1D, market cap $605.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NVCT ranks #546 in composite RQD confidence.

How does NVCT compare to GERN and IRWD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVCT carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GERN (Geron Corporation) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C+ grade (69/100 RQD, P/E 24.9x, ROIC 85.0%, cap $598.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NVCT?

Per NVCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875558), Nuvectis Pharma Inc. generated $0 in revenue, -$26.4M in net income, and -$16.0M in free cash flow against $31.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NVCT trading relative to its 50-day, 200-day, and 52-week technical levels?

NVCT last traded at $18.57 (+1.14% on volume of 117,692 shares), positioning the stock -13.43% below its 50-day simple moving average ($21.45) and +27.10% above its 200-day simple moving average ($14.61). Across its 52-week range of $5.55 to $29.28, NVCT sits at the 54.9% percentile with a 14-day RSI of 41.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.25 to $20.89).

NVCT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NVCT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for NVCT.

Direct Sub-Reports: NVCT RQD Cockpit NVCT 12M Forecast NVCT Earnings & Move NVCT Dividends & DRIP NVCT Insiders & 13F NVCT Whale Options NVCT Profit Sankey NVCT News & Why